This site is intended for Healthcare Professionals outside the US

US Residents
Product Characteristics
Safety Information

Email Facebook Linkedin Twitter Close

MF

PV

About MF
Efficacy
Safety
- Nonhaematologic Reactions
- Haematologic Reactions
Dosing
- Starting Dose
- Dose Adjustment
MOA
- JAK Dysregulation
- JAK Inhibitor MOA
Study Design
- COMFORT-1
- COMFORT-2

About PV
Efficacy
Safety
- Well-Characterised Safety Profile
- Safety Profile in RESPONSE
Dosing
- Recommendations
Study Design
- RESPONSE
MOA
- JAK Dysregulation and JAKAVI MOA

404

Page not found

Terms of Use
Privacy Policy
Contact Us
Site Map

Disclaimer: This is an international website for JAKAVI^® (ruxolitinib) and is intended for healthcare professionals outside the US. The information on the site is not country-specific, and may contain information that is outside of the approval in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

© 2020 NOVARTIS AG. All Rights Reserved.

You are now leaving the Jakavi.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

This is an international site for Jakavi^® (ruxolitinib) and is intended for healthcare professionals outside the US.

JAKAVI^® (ruxolitinib) is approved for use in 82 countries around the world.

Healthcare Professionals
Patients

Austria Germany Japan United States